Clinical Research
corporate_fare

Genentech Inc.

Address
1 Dna Way

Sponsor Overview

assignment
36
sponsored trials
science
20
molecules
location_city
321
research centres
public
16
countries
person_search
487
investigators

Specializations

Oncology

Genentech Inc. funds a broad oncology portfolio spanning advanced melanoma, non-small cell lung cancer, metastatic breast cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and advanced prostate cancer. Its studies also include HER2-expressing cancers, KRAS G12C-mutated solid tumors, and other locally advanced or metastatic solid tumors.

  • Advanced melanoma and NRAS-mutant melanoma
  • Breast cancer with ER-positive, HER2-negative disease
  • KRAS-mutant solid tumors and metastatic gastrointestinal cancers
  • B-cell malignancies and multiple myeloma

Research activity also extends to relapsed or refractory multiple myeloma, B-cell malignancies, and other hematologic cancers, alongside solid-tumor programs that target difficult-to-treat metastatic disease.

Respiratory and Fibrotic Disease

The sponsor supports research in chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and systemic sclerosis-associated interstitial lung disease. These programs reflect interest in chronic inflammatory and fibrotic conditions affecting lung function and respiratory health.

  • Chronic obstructive pulmonary disease (COPD)
  • Idiopathic pulmonary fibrosis
  • Systemic sclerosis-associated interstitial lung disease

Additional work includes systemic sclerosis studies with pulmonary involvement, linking connective tissue disease research with progressive lung impairment.

Immunology and Inflammatory Disease

Genentech’s clinical research includes ulcerative colitis, systemic lupus erythematosus, and systemic sclerosis, with attention to both organ-specific and systemic autoimmune disorders. The portfolio also includes conditions with inflammatory and immune-mediated pathology such as lupus nephritis.

  • Moderately to severely active ulcerative colitis
  • Systemic lupus erythematosus with or without lupus nephritis
  • Systemic sclerosis

These studies address immune dysregulation across gastrointestinal, renal, and connective tissue manifestations.

Rare and Genetic Disorders

The sponsor funds research in late-onset Pompe disease, a glycogen storage disorder with neuromuscular and metabolic consequences. This area adds a rare-disease dimension to its broader therapeutic portfolio.

  • Pompe disease
  • Glycogen storage disease type II

These programs focus on inherited disease biology and long-term functional impairment.

Cardiometabolic and Perioperative Conditions

Genentech also supports studies in acute kidney injury associated with cardiac surgery and in overweight or obesity in otherwise healthy participants. This expands its research landscape into perioperative renal risk and metabolic health.

  • Cardiac surgery-associated acute kidney injury
  • Overweight and obesity

These areas complement its disease-focused programs by addressing complications linked to surgery and body weight.

Sponsored Trials

Trial Name Country Status
A Phase 2 Study to Evaluate the Efficacy and Safety of Cevostamab in Patients with Systemic Lupus Erythematosus With or Without Active Lupus NephritisFrance FranceGermany GermanyItaly ItalySpain SpainRecruiting
A Phase I Study to Evaluate the Safety and Pharmacokinetics of RO7795074 in Overweight or Obese Healthy VolunteersThe Netherlands The NetherlandsNot Recruiting
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal AdenocarcinomaBelgium BelgiumFrance FranceGermany GermanySpain SpainSweden SwedenThe Netherlands The NetherlandsRecruiting
A Phase IIb, Multicenter, Double-Blind, Placebo-Controlled Induction Study with an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients with Moderately to Severely Active Ulcerative ColitisCzechia CzechiaFrance FranceGermany GermanyItaly ItalyPoland PolandRecruiting
A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients with Systemic Sclerosis-Associated Interstitial Lung DiseaseBelgium BelgiumFrance FranceGermany GermanyGreece GreeceHungary HungaryItaly ItalyPoland PolandSpain SpainNot Recruiting
Dose-Escalation Study of Cevostamab in Patients with Relapsed or Refractory Multiple MyelomaSpain SpainNot Recruiting
Dose-Escalation Study of XmAb24306 Alone and with Atezolizumab in Patients with Locally Advanced or Metastatic Solid TumorsBelgium BelgiumItaly ItalySpain SpainThe Netherlands The NetherlandsNot Recruiting
Efficacy and Safety Evaluation of Astegolimab in Chronic Obstructive Pulmonary Disease: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb StudyBelgium BelgiumBulgaria BulgariaCzechia CzechiaDenmark DenmarkFrance FranceGermany GermanyPoland PolandRomania RomaniaSpain SpainSweden SwedenThe Netherlands The NetherlandsNot Recruiting
Efficacy and Safety Evaluation of Autogene Cevumeran and Pembrolizumab Versus Pembrolizumab Monotherapy in Treatment-Naïve Advanced Melanoma PatientsGermany GermanySpain SpainNot Recruiting
Efficacy and Safety of Giredestrant Plus Everolimus Versus Endocrine Therapy Plus Everolimus in ER-Positive, HER2-Negative Advanced Breast CancerGermany GermanyGreece GreeceItaly ItalySpain SpainNot Recruiting
1–10 of 36
1 / 4

Data & Insights

science
Molecule Portfolio
Compounds under investigation
4
Exclusive Molecules
out of 20 total (20% not shared with other sponsors)

This sponsor works with 20 molecules, of which 4 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
32%
Return partnership rate
102 of 321 sites collaborated multiple times

This sponsor has worked with 321 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Neoplasms24 trials
    853 other sponsors
  • 2.
    Respiratory Tract Diseases4 trials
    277 other sponsors
  • 3.
    Digestive System Diseases3 trials
    280 other sponsors
  • 4.
    Immune System Diseases3 trials
    322 other sponsors
  • 5.
    Nutritional and Metabolic Diseases3 trials
    211 other sponsors
  • 6.
    Immune System Phenomena2 trials
    15 other sponsors
  • 7.
    Cardiovascular Diseases1 trial
    359 other sponsors
  • 8.
    Congenital, Hereditary, and Neonatal Diseases and Abnormalities1 trial
    165 other sponsors
  • 9.
    Environment and Public Health1 trial
    7 other sponsors
  • 10.
    Not possible to specify1 trial
    220 other sponsors
  • 11.
    Physical Phenomena1 trial
    3 other sponsors
  • 12.
    Skin and Connective Tissue Diseases1 trial
    247 other sponsors

Partnered Research Centres

321 centres
location_city
assignment32
1 Wojskowy Szpital Kliniczny Z Poliklinika samodzielny publiczny zakład opieki zdrowotnej W Lublinie
Address
Ul. Aleje Raclawickie 23, 20-049 Lublin
Learn morearrow_forward
location_city
assignment335
Aalborg University Hospital
Address
Moelleparkvej 4, 9000 Aalborg
Learn morearrow_forward
location_city
assignment247
Alexandra Hospital
Address
Vassilissis Sofias Avenue 80, 115 28 Athens
Learn morearrow_forward
location_city
assignment283
Algemeen Ziekenhuis Delta
Address
Deltalaan 1, 8800 Roeselare
Learn morearrow_forward
location_city
assignment28
Allmedica Badania Kliniczne Sp. z o.o.
Address
Ul. Kowaniec 2a, 34-400 Nowy Targ
Learn morearrow_forward
location_city
assignment192
Amphia Hospital
Address
Molengracht 21, 4818 CK Breda
Learn morearrow_forward
Page 1 of 54

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Genentech Inc..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.